Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats

Journal of Applied Toxicology

Volumn 28, Issue 3, 2008, Pages 388-398

  Uehara, Takeki ^a   Tsuchiya, Noriko ^a   Masuda, Aki ^a   Torii, Mikinori ^a   Nakamura, Masuhisa ^b   Yamate, Jyoji ^c   Maruyama, Toshiyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c Osaka Prefecture University   (Japan)

Author keywords

Amelioration; Hydration; Nedaplatin; Nephrotoxicity; Rat

Indexed keywords

NEDAPLATIN; PLATINUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM; HISTOPATHOLOGY; HYDRATION; KIDNEY COLLECTING TUBULE; KIDNEY CONCENTRATING CAPACITY; KIDNEY DISTAL TUBULE; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SINGLE DRUG DOSE; TISSUE REPAIR; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BODY WATER; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; EATING; FLUID THERAPY; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TUBULES; LONGEVITY; MALE; ORGANOPLATINUM COMPOUNDS; RATS; TIME FACTORS; WATER-ELECTROLYTE BALANCE;

RATTUS;

EID: 42049123667     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1292     Document Type: Article

References (36)

1. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y. 1992. Phase II study of cis-diammine-(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother. Pharmacol. 31: 187-192.
2. Ali BH, Al Moundhri MS. 2006. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem. Toxicol. 44: 1173-1183.
3. Arany I, Safirstein RL. 2003. Cisplatin nephrotoxicity. Semin. Nephrol. 23: 460-464.
4. Bozzino JM, Prasad V, Koriech OM. 1981. Avoidance of renal toxicity by 24-hour infusion of cisplatin. Cancer Treat. Rep. 65: 351-352.
5. Cornelison TL, Reed E. 1993. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol. Oncol. 50: 147-158.
6. Daugaard G, Abildgaard U. 1989. Cisplatin nephrotoxicity. A review. Cancer Chemother. Pharmacol. 25: 1-9.
7. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH. 1978. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41: 1274-1281.
8. Dobyan DC. 1985. Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat. Rec. 212: 239-245.
9. Dobyan DC, Hill D, Lewis T, Bulger RE. 1981. Cyst formation in rat kidney induced by cis-platinum administration. Lab. Invest. 45: 260-268.
10. Fichtinger-Schepman AM, Vendrik CP, van Dijk-Knijnenburg WC, de Jong WH, van der Minnen AC, Claessen AM, van der Velde-Visser SD, de Groot G, Wubs KL, Steerenberg PA, Schornagel, JH, Berends F. 1989. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma. Cancer Res. 49: 2862-2867.
11. Fjeldborg P, Sorensen J, Helkjaer PE. 1986. The long-term effect of cisplatin on renal function. Cancer 58: 2214-2217.
12. Freireich EJ, Gehan EA, Rail DP, Schmidt LH, Skipper HE. 1966. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. 50: 219-244.
13. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N. 1990. Phase II study of (glycolato-O,O) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother. Pharmacol. 26: 393-396.
14. Gavrieli Y, Sherman Y, Ben-Sasson SA. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119: 493-501.
15. Goldstein RS, Mayor GH. 1983. Minireview. The nephrotoxicity of cisplatin. Life Sci. 32: 685-690.
16. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. 1977. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39: 1362-1371.
17. Groth S, Nielsen H, Sorensen JB, Christensen AB, Pedersen AG, Rorth M. 1986. Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother. Pharmacol. 17: 191-196.
18. Hamilton CR, Bliss JM, Horwich A. 1989. The late effects of cis-platinum on renal function. Eur. J. Cancer Clin. Oncol. 25: 185-189.
19. Hartmann JT, Lipp HP. 2003. Toxicity of platinum compounds. Expert Opin. Pharmacother. 4: 889-901.
20. Heinegard D, Tiderstrom G. 1973. Determination of serum creatinine by a direct colorimetric method. Clin. Chim. Acta 43: 305-310.
21. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K. 1992. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 19: 871-877.
22. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, Ota M. 1992. Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho 19: 695-701.
23. Litterst CL, LeRoy AF, Guarino AM. 1979. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals. Cancer Treat. Rep. 63: 1485-1492.
24. Megyesi J, Safirstein RL, Price PM. 1998. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J. Clin. Invest. 101: 777-782.
25. Meyer KB, Madias NE. 1994. Cisplatin nephrotoxicity. Miner. Electrolyte Metab. 20: 201-213.
26. Ota K. 1996. Nedaplatin. Gan To Kagaku Ryoho 23: 379-387.
27. Ota K, Wakui A, Majima H, Niitani H, Inuyama Y, Ogawa M, Ariyoshi Y, Yoshida O, Taguchi T, Kimura I. 1992. Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Gan To Kagaku Ryoho 19: 855-861.
28. Posner MR, Skarin AT, Clark J, Ervin TJ. 1986. Phase I study of continuous-infusion cisplatin. Cancer Treat. Rep. 70: 847-850.
29. Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV. 2003. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother. Pharmacol. 52: 13-18.
30. Smith PHS, Taylor DM. 1974. Distribution and retention of the antitumour agent 195M-PT-cis-dichlorodiammineplatinum (II) in man. J. Nucl. Med. 15: 349-351.
31. Taguchi T, Nazneen A, Abid MR, Razzaque MS. 2005. Cisplatin-associated nephrotoxicity and pathological events. Contrib. Nephrol. 148: 107-121.
32. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K. 1992. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Gan To Kagaku Ryoho 19: 483-488.
33. Tanaka H, Nagasaki T, Okabe H, Utida N, Norikura R, Inazawa K, Yamauchi A, Katsuyama Y, Segawa K, Murakami T, Adachi Y, Mizojiri K, Matsubara T, Kawai K, Akaboshi M. 1995. Studies on the disposition of a new antineoplastic agent, nedaplatin. Whole-body autoradiography, blood concentration and excretion of [195mPt]nedaplatin following intravenous administration in rats. Iyakuhin Kenkyu 26: 887-895.
34. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, Maruyama T. 2005. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch. Toxicol. 79: 451-460.
35. Yamate J, Ishida A, Tsujino K, Tatsumi M, Nakatsuji S, Kuwamura M, Kotani T, Sakuma S. 1996. Immunohistochemical study of rat renal interstitial fibrosis induced by repeated injection of cisplatin, with special reference to the kinetics of macrophages and myofibroblasts. Toxicol. Pathol. 24: 199-206.
36. Yamate J, Sato K, Ide M, Nakanishi M, Kuwamura M, Sakuma S, Nakatsuji S. 2002. Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet. Pathol. 39: 322-333.